Trial · NCT01808313
Results by group328
Each measurement the trial posted, group by group, in the words and numbers it posted.
21 to 40 of 328
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
Number of Participants With the Indicated Event, as an Assessment of Time to Clinical Worsening of Pulmonary Arterial Hypertension (PAH) up to Week 24, Assessed as the First Occurrence of a Particular Event | Ambrisentan | IP discon (additional medication) at Week 12 | 0 | Participants | |
Number of Participants With the Indicated Event, as an Assessment of Time to Clinical Worsening of Pulmonary Arterial Hypertension (PAH) up to Week 24, Assessed as the First Occurrence of a Particular Event | Ambrisentan | Death at Week 24 | 3 | Participants | |
Number of Participants With the Indicated Event, as an Assessment of Time to Clinical Worsening of Pulmonary Arterial Hypertension (PAH) up to Week 24, Assessed as the First Occurrence of a Particular Event | Ambrisentan | Lung Transplant at Week 24 | 0 | Participants | |
Number of Participants With the Indicated Event, as an Assessment of Time to Clinical Worsening of Pulmonary Arterial Hypertension (PAH) up to Week 24, Assessed as the First Occurrence of a Particular Event | Ambrisentan | Hospitalization for PAH at Week 24 | 1 | Participants | |
Number of Participants With the Indicated Event, as an Assessment of Time to Clinical Worsening of Pulmonary Arterial Hypertension (PAH) up to Week 24, Assessed as the First Occurrence of a Particular Event | Ambrisentan | Atrial Septostomy at Week 24 | 0 | Participants | |
Number of Participants With the Indicated Event, as an Assessment of Time to Clinical Worsening of Pulmonary Arterial Hypertension (PAH) up to Week 24, Assessed as the First Occurrence of a Particular Event | Ambrisentan | IP discon (additional medication) at Week 24 | 0 | Participants | |
| Number of Participants With Any Adverse Events, Any Serious Adverse Events and Adverse Events Leading to Discontinuation | Ambrisentan | Any AEs | 91 | Participants | |
| Number of Participants With Any Adverse Events, Any Serious Adverse Events and Adverse Events Leading to Discontinuation | Ambrisentan | Any SAEs | 11 | Participants | |
| Number of Participants With Any Adverse Events, Any Serious Adverse Events and Adverse Events Leading to Discontinuation | Ambrisentan | AEs leading to discontinuation | 4 | Participants | |
| Number of Participants With Physical Examination Findings | Ambrisentan | NA | Participants | ||
| Change From Baseline in Electrocardiogram (ECG) Heart Rate Values at Weeks 12 and 24 | Ambrisentan | Week 12, n=124 | -2.0 | Standard Deviation 16.65 | Beats per minute |
| Change From Baseline in Electrocardiogram (ECG) Heart Rate Values at Weeks 12 and 24 | Ambrisentan | Week 24, n=118 | -4.6 | Standard Deviation 14.68 | Beats per minute |
| Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Interval Corrected Bazett's Formula (QTcB) Values at Weeks 12 and 24 | Ambrisentan | PR interval, Week 12, n=122 | 0.7 | Standard Deviation 16.55 | Milliseconds |
| Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Interval Corrected Bazett's Formula (QTcB) Values at Weeks 12 and 24 | Ambrisentan | PR interval, Week 24, n=117 | 1.5 | Standard Deviation 14.84 | Milliseconds |
| Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Interval Corrected Bazett's Formula (QTcB) Values at Weeks 12 and 24 | Ambrisentan | QRS duration, Week 12, n=124 | -1.5 | Standard Deviation 15.84 | Milliseconds |
| Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Interval Corrected Bazett's Formula (QTcB) Values at Weeks 12 and 24 | Ambrisentan | QRS duration, Week 24, n=118 | 0.7 | Standard Deviation 14.40 | Milliseconds |
| Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Interval Corrected Bazett's Formula (QTcB) Values at Weeks 12 and 24 | Ambrisentan | Uncorrected QT Interval, Week 12, n=124 | -0.7 | Standard Deviation 37.44 | Milliseconds |
| Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Interval Corrected Bazett's Formula (QTcB) Values at Weeks 12 and 24 | Ambrisentan | Uncorrected QT Interval, Week 24, n=118 | 6.8 | Standard Deviation 40.41 | Milliseconds |
| Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Interval Corrected Bazett's Formula (QTcB) Values at Weeks 12 and 24 | Ambrisentan | Corrected QTcB interval, Week 12, n=123 | -4.9 | Standard Deviation 29.74 | Milliseconds |
| Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Interval Corrected Bazett's Formula (QTcB) Values at Weeks 12 and 24 | Ambrisentan | Corrected QTcB interval, Week 24, n=117 | -1.5 | Standard Deviation 37.25 | Milliseconds |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01808313/results?page=2